Pharma BD Deal Intelligence

Recordati S.p.A. / EUSA Pharma (UK) Ltd.

2022 · Acquisition/Merger · $845M · Complete

Recordati closed acquisition of EUSA Pharma for ~$845M (€750M enterprise value), adding four rare-cancer products: Qarziba (anti-GD2 mAb in neuroblastoma), Sylvant (anti-IL-6 mAb in Castleman disease), Fotivda (TKI in RCC), and Caphosol (oral mucositis). Closed March 16, 2022.

Key facts

• Announced Mar 16, 2022
• Closed Mar 16, 2022
• Deal value $845M
• Deal type Acquisition/Merger
• Therapeutic area Rare/niche oncology (high-risk neuroblastoma; Castleman; RCC; mucositis)
• Indications Rare/niche oncology (high-risk neuroblastoma; Castleman; RCC; mucositis)
• Key assets Qarziba (dinutuximab beta), Sylvant (siltuximab), Fotivda (tivozanib), Caphosol
• Mechanism Anti-GD2 mAb; anti-IL-6 mAb; oral VEGFR TKI; oral mucositis device

← Browse all deals  ·  How we score deals